Press release
2024-12-19
ImmuneBiotech and Lund University Launch a Pioneering Clinical Study Linking Gut Health to Preeclampsia Prevention2024-10-14
ImmuneBiotech Medical Sweden AB Strengthens Leadership with Strategic Appointment of Rickard Mosell as Chairman of the Board2023-05-11
ImmuneBiotech Medical Sweden AB announces the appointment of international microbiome expert Kristin Wannerberger to board of directors2021-01-20
ImmuneBiotech closes fully subscribed new share issue with funding from recognized investors and existing shareholders2020-09-22
ImmuneBiotech: Patent granted for GutMagnific® in the United States2020-06-10
ImmuneBiotech: starts clinical trial of GutMagnific® in ME/CFS in collaboration with Stora Sköndal ME clinic2019-10-16
ImmuneBiotech: market launch of first product GutMagnific2019-05-07
ImmuneBiotech: Winner of H2020 “SME Instrument” Phase 1
News
July, 2024
ImmuneBiotech AB is excited to share this insightful podcast featuring our CEO, Dr. Shahram Lavasani!May, 2024
ImmuneBiotech team attended VitafoodsEurope 2024May, 2024
Dr. Lavasani´s interview on “The role of gut microbiota and mycobiota in pre-eclampsia”May, 2024
ImmuneBiotech AB team just ended 3 productive days at Probiota 2024January, 2024
ImmuneBiotech’s End-Of-The-Year MessageNovember, 2023
ImmuneBiotech’s 10th anniversaryNovember, 2023
Our CEO Dr Shahram Lavasani is currently in the USA at the Microbiome Movement-Human Nutrition conference.November, 2023
Our CEO Shahram Lavasani was invited keynote speaker at Plovdiv University (Bulgaria) at the “Biotechnologies for Personalized Medicine” conference.
Press contact
For media inquiries, please write to info@immunebiotech.com
ImmuneBiotech AB
Scheelevägen 2, Medicon Village
223 81 Lund, Sweden
Phone: +46 46 25 25 50
GutMagnific Web Shop: www.GutMagnific.com
Follow us on LinkedIn for the latest updates and information.